Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096056 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL4316806 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL12228287 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL4316809 | 0.80 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL23054324 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL22096057 | 0.68 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL23928002 | 0.68 | SMN1; SMN2 (0.57) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL8711763 | 0.65 | HRH3 (0.56) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL15483527 | 0.65 | SMN1; SMN2 (0.48) | SMN1; SMN2GAAHRH4HTR3AHRH3 | |
| SCHEMBL24614238 | 0.64 | HDAC4 (0.49) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820834-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | NOVMETAPHARMA CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820834-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | GLS, ENPEP, PRCP | SMN1; SMN2 4517/4885GAA 1553/4885HRH4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.